ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Tumor Infiltrating Lymphocytes LN-145

Also written as “LN-145”, “Autologous Tumor Infiltrating Lymphocytes” and “LN-145/LN-144”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Sarcoma · Uterine Cervical Neoplasms · Melanoma · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageAutologous Tumor Infiltrating Lymphocytes LN-145: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 14, 20178 company-led studies, 3 open or runningNext primary completion: Jan 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Iovance Biotherapeuticsits history only61 open or runningphase 2since Mar 14, 2017Mar 14, 2017Dec 2030phase 2 · NCT04614103
Shanghai Juncell Therapeutics22 open or runningphase 2since Apr 24, 2026Jun 18, 2024Jan 1, 2027phase 1 · NCT06473961

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shanghai Juncell Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 18, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06473961 · 20 planned · China
  2. Apr 24, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07560111 · 28 planned · China

Ahead

  1. Jan 1, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06473961
  2. Jun 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07560111

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Shanghai Juncell Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07560111Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 1, 202728
NCT06473961Carcinoma, Non-Small-Cell Lung · China1RecruitingJan 1, 202720

How it is read

Names in the registry

  • “LN-145”, 6 entries
  • “Autologous Tumor Infiltrating Lymphocytes”, 2 entries
  • “LN-145/LN-144”, 1 entry
  • “LN-145 + pembrolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.